Comparison of Novel Biomarkers of Insulin Resistance With Homeostasis Model Assessment of Insulin Resistance, Its Correlation to Metabolic Syndrome in South Indian Population and Proposition of Population Specific Cutoffs for These Indices.
homa-ir
insulin resistance
lipid accumulation product
metabolic syndrome
tg: hdl ratio
tyg index
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
26
12
2022
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
16
2
2023
Statut:
epublish
Résumé
Background The clustering of risk factors of cardiovascular disease (CVD) in individuals has been defined as Metabolic Syndrome (MetS). The major forerunner of all the components of MetS is Insulin Resistance (IR) which is measured by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and requires the measurement of fasting plasma insulin levels. We attempted to study the performance of lipid-based biochemical markers of IR for the diagnosis of MetS and postulate a population-specific cutoff for these indices in the South Indian population. In this study, we analyzed three lipid-based indices, Triglyceride Glucose index (TyG index), triglyceride: high-Density Lipoprotein (TG:HDL) ratio, and lipid accumulation product (LAP). Methods This was a cross-sectional study and included apparently healthy individuals presenting to our hospital for routine Master Health Checkup assessment and apparently healthy population residing in Kallindhiri, a village near Madurai. Based on the anthropometric measurements and blood investigations, Body Mass Index (BMI), Waist hip ratio, Waist height ratio, HOMA-IR, TyG index, TG:HDL ratio, and LAP were calculated. The diagnostic efficacy of these indices was compared against the presence of MetS based on the NCEP ATP III criteria. The receiver operating characteristic (ROC) Curve was performed to discriminate decision levels (cutoffs) of serum markers in early diagnosis of metabolic syndrome. The results were considered significant with a p-value less than 0.05. Results We included a total of 192 patients in our study, consisting of 36% (n=70) males and 63% (n=122) females. All the baseline characteristics except height, weight, and HDL cholesterol were comparable between the male and female groups. The values of HOMA-IR, TyG index, TG:HDL ratio, and LAP showed an increasing trend with the BMI. The mean values of HOMA-IR, TyG index, TG:HDL ratio and LAP was significantly higher in patients with MetS than in patients without MetS. Based on the ROC curve plotted for the data, a population-specific cutoff for these indices was computed. Our proposed cutoff for the South Indian population for HOMA-IR is 1.23, for TyG index is 4.65, for TG:HDL ratio is 3.44 in males and 2.6 in females and for LAP is 43.81 Conclusion The cutoffs for the novel indices of insulin resistance which have been previously studied in Caucasian populations cannot be applied to Indian populations due to distinct ethnic characteristics. The diagnostic accuracy of these novel lipid-based biomarkers of Insulin Resistance is better than the biochemical gold standard of HOMA-IR based on the ROC curve. We propose the usage of these population-specific cutoffs in routine clinical practice for early diagnosis of metabolic syndrome.
Identifiants
pubmed: 36788883
doi: 10.7759/cureus.33653
pmc: PMC9915858
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e33653Informations de copyright
Copyright © 2023, Jog et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Indian J Endocrinol Metab. 2022 Jul-Aug;26(4):295-318
pubmed: 36185955
Diabet Med. 1999 May;16(5):442-3
pubmed: 10342346
Diabetes Care. 2011 Aug;34(8):1869-74
pubmed: 21730284
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
BMC Cardiovasc Disord. 2012 Sep 24;12:78
pubmed: 23006530
BMC Endocr Disord. 2013 Oct 16;13:47
pubmed: 24131857
BMJ Open Diabetes Res Care. 2021 Sep;9(1):
pubmed: 34531243
J Diabetes Complications. 2016 Mar;30(2):287-91
pubmed: 26718937
J Clin Res Pediatr Endocrinol. 2013;5(4):245-51
pubmed: 24379034
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):113-118
pubmed: 28217509
PLoS One. 2020 Oct 19;15(10):e0240971
pubmed: 33075086
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
BMC Cardiovasc Disord. 2005 Sep 08;5:26
pubmed: 16150143
J Cardiovasc Dis Res. 2012 Jul;3(3):204-11
pubmed: 22923938
BMJ Open. 2021 Mar 22;11(3):e041519
pubmed: 33753431
Arch Med Res. 2016 Jul;47(5):382-387
pubmed: 27751372
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Cardiovasc Diabetol. 2020 Nov 22;19(1):195
pubmed: 33222691
PLoS Med. 2020 Apr 30;17(4):e1003100
pubmed: 32353039
Sci Rep. 2019 May 13;9(1):7320
pubmed: 31086234
Metab Syndr Relat Disord. 2018 Jun;16(5):240-245
pubmed: 29648916
Am J Cardiol. 2008 Aug 15;102(4):424-8
pubmed: 18678299
J Clin Neurosci. 2017 Jun;40:34-38
pubmed: 28268148
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
JAMA. 2021 Apr 27;325(16):1657-1669
pubmed: 33904862
J Family Med Prim Care. 2021 Oct;10(10):3700-3705
pubmed: 34934668
Clin Exp Nephrol. 2019 Jul;23(7):948-955
pubmed: 30955189
World J Cardiol. 2016 Mar 26;8(3):247-57
pubmed: 27022456
Diabetes. 2003 May;52(5):1210-4
pubmed: 12716754